Eagle Pharmaceuticals Inc
NASDAQ:EGRX
Eagle Pharmaceuticals Inc
Revenue
Eagle Pharmaceuticals Inc
Revenue Peer Comparison
Competitive Revenue Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Eagle Pharmaceuticals Inc
NASDAQ:EGRX
|
Revenue
$257.5m
|
CAGR 3-Years
13%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
Abbvie Inc
NYSE:ABBV
|
Revenue
$54.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
11%
|
CAGR 10-Years
11%
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Revenue
$27.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
7%
|
|
Amgen Inc
NASDAQ:AMGN
|
Revenue
$28.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Revenue
$9.9B
|
CAGR 3-Years
17%
|
CAGR 5-Years
26%
|
CAGR 10-Years
23%
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Revenue
$13.1B
|
CAGR 3-Years
16%
|
CAGR 5-Years
14%
|
CAGR 10-Years
20%
|
Eagle Pharmaceuticals Inc
Revenue Breakdown
Breakdown by Geography
Eagle Pharmaceuticals Inc
Breakdown by Segments
Eagle Pharmaceuticals Inc
Total Revenue:
316.6m
USD
|
Product Sales, Net:
214.5m
USD
|
Royalty Revenue:
98.3m
USD
|
Pemfexy:
67.5m
USD
|
Vasopressin:
63.2m
USD
|
Belrapzo:
33.7m
USD
|
Ryanodex:
30.2m
USD
|
Bendeka:
13m
USD
|
Other:
7.1m
USD
|
License And Other Revenue:
3.8m
USD
|
See Also
What is Eagle Pharmaceuticals Inc's Revenue?
Revenue
257.5m
USD
Based on the financial report for Jun 30, 2023, Eagle Pharmaceuticals Inc's Revenue amounts to 257.5m USD.
What is Eagle Pharmaceuticals Inc's Revenue growth rate?
Revenue CAGR 5Y
4%
Over the last year, the Revenue growth was -5%. The average annual Revenue growth rates for Eagle Pharmaceuticals Inc have been 13% over the past three years , 4% over the past five years .